Efficacy News and Research

RSS
Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

FEV1 poor mortality predictor in elderly

FEV1 poor mortality predictor in elderly

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

Combination of heat, doxorubicin drug and nanotech system may improve ovarian cancer treatment

Combination of heat, doxorubicin drug and nanotech system may improve ovarian cancer treatment

AmpliPhi, University of Leicester partner to develop novel bacteriophage therapy against C. difficile

AmpliPhi, University of Leicester partner to develop novel bacteriophage therapy against C. difficile

CardioFocus completes HeartLight EAS pivotal trial enrollment for symptomatic paroxysmal AF

CardioFocus completes HeartLight EAS pivotal trial enrollment for symptomatic paroxysmal AF

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

BRAF inhibitor vemurafenib effective for patients with papillary thyroid cancer

BRAF inhibitor vemurafenib effective for patients with papillary thyroid cancer

ESTEVE reports positive top line results from E-58425 phase II trial for acute pain

ESTEVE reports positive top line results from E-58425 phase II trial for acute pain

Results of Phase 3 clinical trial of contraceptive vaginal ring presented by Population Council

Results of Phase 3 clinical trial of contraceptive vaginal ring presented by Population Council

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Study illuminates definitive brain alterations in troops with Gulf War Illness

Study illuminates definitive brain alterations in troops with Gulf War Illness

House dust mite allergy treatment: an interview with Steve Harris, CEO & Co-founder of Circassia

House dust mite allergy treatment: an interview with Steve Harris, CEO & Co-founder of Circassia

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Viewpoints: Marketplaces' 'technical foibles' may keep young people from coming back; health law may be ushering in era of narrow networks

Viewpoints: Marketplaces' 'technical foibles' may keep young people from coming back; health law may be ushering in era of narrow networks

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.